Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Down 5.90%
As of Friday, July 31, Alto Neuroscience, Inc.’s ANRO share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Commentary & Analysis
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Down 6.26%
As of Friday, July 10, Alto Neuroscience, Inc.’s ANRO share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Michael Rose
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Up 6.10%
As of Wednesday, June 24, Alto Neuroscience, Inc.’s ANRO share price has surged by 6.10%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Up 8.85%
As of Tuesday, June 23, Alto Neuroscience, Inc.’s ANRO share price has surged by 8.85%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Up 10.40%
As of Tuesday, June 23, Alto Neuroscience, Inc.’s ANRO share price has surged by 10.40%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,112.9 | $569.9 | 46% |
|
| Shares Out (Mil) | 32.9 | 44.8 | 39% |
|
| Institutional Ownership | 95.7% | 84.6% | 68% |
|
| Float (Mil) | 25.2 | 45.1 | 33% |
|
| Beta | 1.25 | 0.67 | 73% |
|
| Avg Daily Volume (000s) | 434 | 294 | 57% |
|
| Price Change (52-week) |
838.7% | 65.2% | 100% |
|
| Growth | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.773) | ($3.145) | ($3.433) | |
| Month Ago EPS | ($0.773) | ($3.145) | ($3.433) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.500) | ($2.100) | ($2.275) | |
| Year/Year Chg | (3.1%) | 43.5% | 58.6% | |
| Financials | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($74) | ($11) | 13% |
|
| EPS (TTM) | ($2.451) | ($0.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $103 | $4 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $7 | 33% |
|
| Enterprise Value (Q1) (Mil) | $450 | $493 | 33% |
|
| Valuation | ANRO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.13 | 2.89 | 74% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (33.2%) | (25.5%) | 16% |
|
| ROE | (38.9%) | (21.4%) | 18% |
|
| Liabilities to Assets | 11.9% | 35.5% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Alto Neuroscience, Inc. did not pass any screens on 7/30/2026.
